


PHARMACEUTICAL 2022

IVERIC bio Inc. Rank 172 of 475





PHARMACEUTICAL 2022

IVERIC bio Inc. Rank 172 of 475

The relative strengths and weaknesses of IVERIC bio Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of IVERIC bio Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 235% points. The greatest weakness of IVERIC bio Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 64% points.

The company's Economic Capital Ratio, given in the ranking table, is -33%, being 244% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	387,488
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	28,211
Liabilities, Non-Current	619
Other Assets	1,522
Other Compr. Net Income	-93
Other Expenses	0
Other Liabilities	0
Other Net Income	235
Property and Equipment	348
Research and Development	85,068
Revenues	0
Selling, General and Administrative Expense	29,689

Output Variable	Value in 1000 USD
Assets	389,358
Liabilities	28,830
Expenses	114,757
Stockholders Equity	360,528
Net Income	-114,522
Comprehensive Net Income	-114,568
Economic Capital Ratio	-33%